CREATING MAGIC

MagIC Lifescience Secures NIH Syphilis Grant

Grant Award from NIAID, NIH

We're thrilled to share some incredible news: MagIC Lifescience has been awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH)! This grant supports our project: "**Development of a Novel Syphilis Molecular Diagnostic Assay for a Point-of-Care Multiplexed Genital Ulcer Panel Test on Giant Magnetoresistive Biosensors.**" We're ready to take on some of the toughest challenges in diagnostics and bring better healthcare outcomes through our MagChipR platform! You can read the official announcement of the grant award here: https://www.nih.gov/news-events/news-releases/nih-awards-will-support-innovation-syphilis-diagnostics

Syphilis Diagnostics: A Challenge We're Ready to Tackle

Syphilis is on the rise worldwide, with cases increasing alarmingly in many regions. The World Health Organization estimates that in 2022, 8 million adults aged 15-49 contracted syphilis globally. The Americas alone account for 42% of these new infections, with an estimated 3.37 million cases. Even more concerning, the Centers for Disease Control and Prevention (CDC) reported a staggering 80% increase in syphilis cases between 2018 and 2022.

Despite being a curable infection, delayed diagnosis and treatment continue to lead to severe complications and further transmission. The lack of rapid, accurate, and accessible diagnostic tools poses a significant challenge, particularly in resource-limited settings. Our project seeks to address this urgent need by harnessing the unique capabilities of giant magnetoresistive biosensors to develop a rapid and accurate assay for syphilis detection, which will ultimately be integrated into our comprehensive MagChip Lesion Panel test.

Advancing Infectious Disease Diagnostics

This grant represents a significant milestone in our mission to revolutionize the diagnosis of infectious diseases, including syphilis and other genital ulcer conditions. Our innovative approach leverages giant magnetoresistive (GMR) biosensors to develop a highly accurate, rapid, cost-effective, and user-friendly point-of-care test. This new assay aims to enhance early detection and treatment, ultimately reducing the global burden of sexually transmitted infections (STIs). Thanks to this support from NIH, we're accelerating our research and development to bring this groundbreaking solution to healthcare providers and patients faster than ever before. We're honored by this recognition and can't wait to share our exciting progress.

Stay tuned for more updates as we advance diagnostics, delivering faster results and better outcomes for everyone! Thank you for being part of this incredible journey!

Disclaimer

Research reported in this publication is by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number 1R21AI185972-01. The total amount awarded by this specific grant is $197,897, which constitutes 100% of this project. The content is solely the authors' responsibility and does not necessarily represent the official views of the National Institutes of Health.